0
0
Indian researchers have achieved significant milestones in the fight against neurodegenerative diseases, offering new hope for millions affected by Alzheimer’s and Parkinson’s. Recent discoveries from leading institutes across the country are paving the way for innovative therapies that could transform the treatment landscape for these debilitating disorders.
Unraveling Cellular Secrets at IISc
Scientists at the Indian Institute of Science (IISc), Bengaluru, have made a landmark discovery in understanding how cells release critical chemical messengers—a process central to brain function and metabolic health. The team uncovered the pivotal role of a fat molecule, PIP2, in regulating the release of neurotransmitters from large dense core vesicles within neurons. Disruptions in this process are linked to neurodegenerative diseases such as Alzheimer’s and Parkinson’s, as well as diabetes.
Using advanced ultra-microelectrode techniques, the researchers observed in real time how PIP2 levels influence vesicle behavior. Their findings suggest that modulating this pathway could lead to new drugs that restore proper neurotransmitter and insulin release, potentially improving outcomes for patients with Alzheimer’s, Parkinson’s, and diabetes.
Innovative Molecules from Pune for Alzheimer’s
At the Agharkar Research Institute in Pune, scientists have developed new synthetic molecules designed to treat Alzheimer’s disease. These molecules, created through a rapid one-pot reaction, have shown effectiveness in laboratory tests by targeting cholinesterase enzymes. By increasing acetylcholine levels—a neurotransmitter vital for memory and cognition—these compounds may help counteract the memory loss and cognitive decline characteristic of Alzheimer’s. Researchers believe these molecules could also be adapted for Parkinson’s therapy and serve as a foundation for dual-action drugs in the future.
Peptidomimetics: A New Class of Neuroprotective Drugs
A team at the Institute of Advanced Study in Science and Technology (IASST) has identified a new class of drugs called peptidomimetics, which mimic natural proteins in the body. These synthetic compounds are more stable and can reach the brain more effectively than traditional protein-based therapies. Designed to protect and regenerate neurons, peptidomimetics have shown promise in preclinical studies for both Alzheimer’s and Parkinson’s, with the added benefit of reduced side effects due to targeted action.
Melatonin Nano-Formulation for Parkinson’s
Researchers at the Institute of Nano Science and Technology (INST), Mohali, have demonstrated that a nano-formulation of melatonin—a hormone known for regulating sleep—can improve brain delivery and therapeutic efficacy in Parkinson’s disease models. This approach enhances the hormone’s neuroprotective and antioxidative properties, helping to clear dysfunctional mitochondria and reduce oxidative stress, both key factors in Parkinson’s progression.
The Road Ahead
These breakthroughs underscore India’s growing leadership in neurodegenerative disease research. While most findings are currently at the laboratory or preclinical stage, they offer a strong foundation for developing targeted, more effective treatments for Alzheimer’s, Parkinson’s, and related disorders.
“This breakthrough holds significant potential for treating Alzheimer’s, Parkinson’s, and diabetes,” said the Indian Institute of Science in a statement.
Disclaimer
This article is based on recent scientific research and announcements. The drugs and therapies described are currently under investigation and have not yet been approved for general clinical use. Patients should consult qualified healthcare professionals before considering any new treatments. The information provided here is for general awareness and should not be taken as medical advice.
Citations:
